A pharmacokinetic (PK) study of AC480 administered twice daily in patients with surgically resectable, recurrent malignant glioma (MG) not on enzyme-inducing antiepileptic drug (EIAED).
A. Desjardins
No relevant relationships to disclose
D. A. Reardon
Consultant or Advisory Role - Roche/Genentech; Schering-Plough
Honoraria - Roche/Genentech; Schering-Plough
J. J. Vredenburgh
Consultant or Advisory Role - Roche/Genentech
Honoraria - Roche/Genentech
K. Peters
No relevant relationships to disclose
M. Trikha
Employment or Leadership Position - Ambit BioSciences
Stock Ownership - Ambit BioSciences
J. James
Employment or Leadership Position - Ambit BioSciences
Stock Ownership - Ambit BioSciences
M. Gardner
Employment or Leadership Position - Ambit BioSciences
Stock Ownership - Ambit BioSciences
A. Brickhouse
No relevant relationships to disclose
J. E. Herndon
No relevant relationships to disclose
H. S. Friedman
Consultant or Advisory Role - Genentech
Honoraria - Genentech